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Related to the Degree of Heart Failure in Patients With Mitral
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NORBERT DOETSCH, MD,* SHIGERU MOTOMURA, MD, MASSUD KHAMSSI, MD,
MARTIN C. MICHEL, MD
Essen, Federal Republic of Germany
In patients suffering from end-stage congestive cardiomy-
opathy, cardiac beta ,-adrenoceptor function is markedly
reduced, whereas cardiac beta -adrenoceptor function is
nearly normal . To determine whether beta, -adrenoceptor
function is impaired in heart failure selectively, beta,- and
beta -adrenoceptor density and functional responsiveness
in the right and left atria and the left papillary muscles
from patients with mitral valve disease (functional class III
to IV) were studied . In all three tissues concomitantly beta 1 -
and beta -adrenoceptor density gradually declined when
the degree of heart failure increased from functional class
III to IV . This decrease in beta,- and beta -adrenoceptor
In heart failure, an increase in the activity of the sympathetic
nervous system in response to the reduced cardiac output
seems to be a general mechanism of the organism to aid the
failing heart (1, ) . Several authors (3-6) have shown that, in
patients suffering from congestive cardiomyopathy, plasma
norepinephrine levels are elevated, reflecting increased sym-
pathetic activity . Although this increased sympathetic activ-
ity may be initially helpful for the failing heart, it simulta-
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density was accompanied by similar decreases in the con-
tractile response of isolated electrically driven right atrial
and left ventricular papillary muscles to beta-adrenergic
agonists .
It is concluded that a decrease in cardiac beta-
adrenoceptor function is a general phenomenon in heart
failure, and its extent is related to the degree of heart
failure . However, in contrast to congestive cardiomyopa-
thy, in mitral valve disease the decrease in cardiac beta-
adrenoceptor function is due to a concomitant decrease in
beta,- and beta -adrenoceptors .
(J Am Coil Cardiol 1989;14 :3 3-31)
3
3
neously can lead to a desensitization of cardiac beta-
adrenoceptors . This occurrence was first demonstrated by
Bristow et al . (7), who showed that in severe heart failure the
number of cardiac beta-adrenoceptors and the inotropic
response to isoproterenol-but not to histamine or calci-
um-were markedly depressed when compared with levels
in the nonfailing heart .
In the last few years, growing evidence has accumulat-
ed that in the human heart beta - in addition to beta,-
adrenoceptors exist . Both beta-adrenoceptor subtypes are
coupled to the adenylate cyclase/cyclic adenosine mono-
phosphate (AMP) system and can contribute to the positive
inotropic effects of beta-adrenoceptor agonists (8) . More-
over, we (9) recently observed that human cardiac beta,- and
beta -adrenoceptors underwent subtype-selective regulation
by beta-adrenoceptor antagonists . Whereas long-term treat-
ment of patients with the beta,-selective antagonists meto-
prolol or atenolol resulted in an increase of cardiac beta,-
(but not cardiac beta ) adrenoceptors, the nonselective beta-
adrenoceptor antagonists sotalol or propranolol concomi-
tantly increased both cardiac beta,- and cardiac beta,-
0735-1097/89/$3 .50
3 4
	
BRODDE ET AL .
JACC Vol . 14, No .
CARDIAC BETA-ADRENOCEPTORS IN MITRAL VALVE DISEASE
August 1989 : 3 3-31
adrenoceptors . Taking into account that norepinephrine-
the main transmitter of the sympathetic nervous system-is
a rather selective beta, -adrenoceptor agonist having a 10 to
30 times greater affinity for beta,- than for beta,-
adrenoceptors (10), it is possible that in heart failure beta,-
but not beta
-adrenoceptors are down regulated selectively .
In fact, Bristow et al. (11) and we (1 ) have found that in
hearts from heart transplant recipients with end-stage con-
gestive cardiomyopathy undergoing orthotopic heart trans-
plantation, the number of cardiac beta ,-adrenoceptors and
the inotropic response to beta-adrenergic stimulation was
selectively reduced, whereas beta,-adrenoceptors were only
marginally altered when compared with those of normal
hearts .
The aim of the present study was to determine whether in
heart failure there is a subtype-selective decrease in cardiac
beta ,-adrenoceptor function . In 35 patients with mitral valve
disease and different degrees of heart failure (New York
Heart Association functional class III to IV), we determined
beta-adrenoceptor density, subtype distribution and function
(contractile responses to beta-adrenergic stimulation) in the
right atrium, left atrium and left ventricular papillary mus-
cles .
Methods
Study patients . Right and left atrial appendages as well as
left ventricular papillary muscles were obtained from 35
patients ( 1 female, 14 male ; mean age 54 .9 ± . [range 16
to 75] years) undergoing mitral valve replacement for mitral
stenosis or mitral regurgitation, or both . Patients were
classified into three groups based on the degree of heart
failure
: group I consisted of 0 patients (1 female, 8 male) in
functional class III, group II of 10 patients (6 female, 4 male)
in class III to IV and group III of 5 patients (3 female, male)
in class IV. The hemodynamic data of these three patient
groups are given in Table 1 . None of the patients had been
treated with beta-adrenoceptor antagonists or had received
catecholamines for ?3 weeks before operation . However,
they had received nitrates (n = 1 ), calcium antagonists (n =
11) and digitalis glycosides (n = 7), alone or in combination .
Surgical procedures . Premeditation usually consisted of
mg flunitrazepam given orally the evening before and on
the morning of operation . Valve replacement was performed
under modified neurolept anesthesia with flunitrazepam and
fentanyl; controlled ventilation was performed, using pancu-
ronium as muscle relaxant, with a 1 :1 mixture of oxygen and
nitrous oxide . Isoflurane was usually avoided . In all patients,
the right atrial appendage was removed during institution of
cardiopulmonary bypass
; the left atrial appendage was am-
putated under normothermic conditions during extracor-
porel circulation ; and the left papillary muscles were ob-
tained when excising the subvalvular apparatus of the mitral
valve . Immediately after excision, all specimens were placed
in sealed vials containing Krebs-Henseleit solution (compo-
sition described later) aerated by Carbogen (95% oxygen, 5%
carbon dioxide) and transported to the laboratory .
Control group . Additionally, right atrial appendages
were obtained from 48 patients (31 male, 17 female ; mean
age 59.4 ± 4.3 [range to 74] years) undergoing coronary
artery bypass grafting who were in functional class I or II .
No patient in this group suffered from acute myocardial
failure or had been treated with catecholamines or beta-
adrenoceptor antagonists for >_3 weeks before operation .
Left papillary muscles were obtained from three female
potential cardiac transplant donors (ages 1 to 50 years)
without evidence of cardiac dysfunction, who had had
trauma-related brain death before the organ procurement .
These three hearts would have been used for heart trans-
plantation except that there was no suitable recipient match
.
Written permission for organ donation was obtained in all
three cases .
Physiologic experiments . The preparation of the myocar-
dial tissues was begun usually within 5 to 0 min of surgical
removal in oxygenated Krebs-Henseleit solution at room
temperature to minimize inadequate oxygenation . The right
and left atrial appendages were dissected to yield trabecular
strips (4 to 5 mm in length and <_1 mm in diameter) without
endocardial damage. The papillary muscles were split longi-
tudinally to obtain strips of the same size or were used as a
whole. The papillary muscles were not used if calcification
could be visually identified . Whenever possible, part of the
same specimens freed from adipose or fibrous tissue was
used for radioligand binding studies .
The preparations were mounted in a 50 ml organ bath
containing Krebs-Henseleit solution of the following compo-
sition (mmol/liter) : sodium chloride 119 ; calcium chloride
.5; potassium chloride 4 .8 ; magnesium sulfate 1 . ; potas-
sium phosphate dibasic 1 . ; sodium bicarbonate 4.9 ; glu-
cose 10.0; ascorbic acid 0 .057, equilibrated with Carbogen at
a temperature of 37°C. The myocardial strips were electri-
cally stimulated by square wave impulses of 5 ms duration
and a voltage about 0% above threshold (range 0 .3 to 1 .3 V,
mean 0.6) at a frequency of stimulation of 1
.0 Hz. The
developed tension of the preparations (maintained under a
rest tension of 4 .9 mN) was recorded through a strain gauge
on a Hellige recorder. All preparations were allowed to
equilibrate for ? h in Krebs-Henseleit solution containing 5
µmol/liter of phenoxybenzamine to block neuronal and
extraneuronal uptake of catecholamines as well as alpha-
adrenoceptors, respectively . After equilibration, washout of
phenoxybenzamine was performed for 1 h . Thereafter, a
submaximal effective concentration of isoproterenol (10'
mol/liter) was administered two or three times until the
successive response remained unchanged . Cumulative con-
centration-response curves for the beta-adrenoceptor ago-
nists were determined as detailed elsewhere (13) .
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Radioligand-binding experiments . For radioligand-bind-
ing studies, membranes were prepared and beta-adreno-
ceptor number was determined by iodine-1 5 iodocyanopin-
dolol (ICYP)-binding at 6 to 8 concentrations of ICYP
ranging from 5 to 00 pmol/liter as recently described (9) .
Nonspecific binding of ICYP was defined as binding to
membranes that is not displaced by a high concentration of
the nonselective beta-adrenoceptor antagonist (±)-CGP
1 177 (1 µmol/liter) . Specific binding of ICYP was defined as
total binding minus nonspecific binding
; it amounted usually
to 70% to 80% at 50 pmol/liter of ICYP
. To determine the
relative amount of beta,- and beta -adrenoceptors in the
preparations, membranes were incubated with ICYP (50
pmol/liter) in the presence or absence of 1 concentrations of
the selective beta -adrenoceptor antagonist ICI 118,551 (14)
and specific binding was determined as described before . ICI
118,551 competition curves were analyzed by the iterative
curve-fitting program LIGAND
(15) . Statistical analysis was
performed with the F ratio test to measure the goodness of fit
of the competition curves for either one or two sites .
Plasma catecholamine determination . Plasma catechol-
amines were assessed by a high performance liquid chro-
matographic method with electrochemical detection .
Statistical evaluations . The experimental data are ex-
pressed as the mean ± SEM of n experiments . The equilib-
rium dissociation constant (KD) and the maximal number of
binding sites (B orax ) were calculated either from plots ac-
cording to Scatchard (16) or by the computer program
LIGAND. The two methods yielded identical results . The
significance of differences in the number of binding sites in
two different groups was estimated by Student's t test . The
relation between two variables was assessed by linear re-
gression analysis . A p value <0.05 was considered to be
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Table 1 . Clinical and Hemodynamic Data of 35 Patients With Mitral Valve Disease
(mean values ± SEM)
LVEF = left ventricular ejection fraction
; NYHA = New York Heart Association
.
3 5
significant; pD values (i
.e ., the negative logarithm of the
molar concentration of agonists causing half-maximal effect)
were determined as described by Van Rossum (17) .
Drugs used . Epinephrine (adrenaline bitartrate), norepi-
nephrine (noradrenaline bitartrate), isoproterenol (isoprena-
line sulfate) and forskolin were purchased from Sigma . ICI
118,551 hydrochloride (erythro-(±)-1-(7-methylindan-4-
yloxy)-3-isopropylaminobutan- -ol) was kindly donated by
ICI Pharma and CGP 071 A (1-[ -(3-carbamoyl-4-hydroxy)
phenoxy ethylamino]-3-[4-(I-methyl-4-trifluoromethyl- -imi-
dazolyl)phenoxy]- -propanol methanesulfonate) and CGP
1
177 hydrochloride (4-[3-tertiarybutylamino- -hydroxypro-
poxy]-benzimidazole- -on) by Ciba Geigy . Procaterol hydro-
chloride was supplied by Otsuka Pharmaceutical Company
and iodine-1 5 iodocyanopindolol (specific activity , 00
Ci/mmole) was obtained from New England Nuclear ; all
other drugs were obtained from sources recently described
(9,13) .
Results
Beta-adrenoceptor number in nonfailing hearts . Mean be-
ta-adrenoceptor density in the right atria obtained from 48
patients undergoing coronary artery bypass grafting without
apparent heart failure (functional class I to II) amounted to
73.6 ± 6.4 fmol ICYP specifically bound/mg protein
. Be-
cause it is not known whether coronary artery disease affects
right atrial beta-adrenoceptor number, it is possible that this
number of beta-adrenoceptors is already slightly reduced .
Mean beta-adrenoceptor number in the left ventricular pap-
illary muscles obtained from the three potential transplant
donors without heart failure was 6 .9 ± 11 .5 fmol ICYP
Group I
(n = 0)
Group 11
(n = 10)
Group Ill
(n = 5)
NYHA functional class 111
III to IV IV
Age (yr) 54 .9 ± 3 .0
54 .0 ± 4 .6 57.0±4.7
Mean right atrial pressure
(mm Hg)
7 .3 ± 1 .0 10 . ± 1 .8 10 .6 ± 1 .8
Mean pulmonary artery pressure
(mm Hg)
31 .9 ± 3 .0 4 .8 ± 4 .1
45 .6 ± 11 .4
Pulmonary vascular resistance
(dynes•s •cm
5
300 ± 88 .8 399 ± 9 .3 16 ± 80
.3
Pulomnary capillary wedge pressure
(mm Hg)
.6
±
.0 5 .3 ± .7 5.5±4.8
LVEF
0 .65 ± 0 .04 0 .6 ± 0 .05 0.56±0 .08
Left ventricular end-diastolic pressure
(mm Hg)
11 .5 ± 0 .7 13 . ± .5 14 .8 ± 3 .4
Cardiac index
(liters/min per m )
.5 ± 0 .1 .5 ± 0 . .3 -±0
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Figure 1. Beta-adrenoceptor densities in appendages from the right
and left atria as well as in left papillary muscles from patients with
mitral valve disease (MVD) in relation to the degree of heart failure
(New York Heart Association [NYHA] functional class) . Ordinate :
Beta-adrenoceptor density in fmol ICYP specifically bound per
milligram protein . Given are mean values ± SEM ; the number of
patients studied is shown at the bottom of each column . ICYP =
iodine- 1 5-iodocyanopindolol .
specifically bound/mg protein, which is slightly less than that
recently described by Bristow et al . (11) .
Beta-adrenoceptor number in patients with mitral valve
disease . In the 35 patients with mitral valve disease, beta-
adrenoceptor number in the right and left atria as well as in
left ventricular papillary muscles gradually declined when
the degree of heart failure increased from functional class III
to IV (Fig . 1) . Whereas in group I (patients in class III) right
atrial beta-adrenoceptor number was only slightly reduced
when compared with that in patients undergoing coronary
artery bypass grafting without apparent heart failure (class I
to II), left ventricular beta-adrenoceptor number was already
reduced by approximately 50%, when compared with that in
nonfailing hearts . Because no data are available on the left
atrial beta-adrenoceptor number in the patients without
heart failure, it is uncertain whether left atrial beta-
adrenoceptor number is decreased in group I patients (class
III). However, left atrial and left ventricular beta-
adrenoceptor densities from the same patients were highly
significantly correlated (Fig . ) . Because left ventricular
beta-adrenoceptor density was obviously decreased in group
I, it may be possible that the same holds true for left atrial
beta-adrenoceptor number .
To determine the relative amount of beta,- and beta
-
adrenoceptors in these tissues, inhibition of ICYP binding by
50
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Figure . Correlation between left ventricular (ordinate) and left
atrial (abscissa) beta-adrenoceptor density in 17 patients with mitral
valve disease . Abbreviations as in Figure 1 .
ICI 118,551 was assessed . This assessment resulted in all
tissues of all patients investigated in competition curves that
fitted significantly better to a two-site than a one-site model .
Thus, for all tissues of all patients the relative amount of
beta,- and beta -adrenoceptors could be calculated (Fig. 1) .
Neither in the right nor the left atrium nor in the left ventricle
did the beta ,/beta -adrenoceptor ratio change with progres-
sion of heart failure ; in addition, in all patients with mitral
valve disease, the beta, /beta -adrenoceptor ratio was not
significantly different from control data obtained in nonfail-
ing hearts, indicating that in mitral valve disease the de-
crease in cardiac beta-adrenoceptor number is due to a
concomitant reduction in beta,-
and beta -adrenoceptors .
Left ventricular beta-adrenoceptor density was similar in
patients with mitral stenosis, mitral regurgitation or com-
bined lesions (Table ). On the other hand, beta-
adrenoceptor density in left atria from patients with mitral
stenosis was markedly higher than in those with mitral
regurgitation or combined mitral lesions, although this did
not reach statistical significance presumably because of the
limited number of patients investigated .
Plasma catecholamine levels in patients with mitral valve
disease . Unfortunately, we could determine plasma cate-
cholamine levels in only 10 of the 35 patients with mitral
Table . Beta-Adrenoceptor Density in Left Atrial Appendage and
Left Papillary Muscle From Patients With Mitral Valve Disease in
Relation to the Hemodynamic Sequelae of the Valve Lesion
Bmax (fmol ICYP specifically
bound/mg protein)
Mitral regurgitation
Mitral stenosis
Combined lesions
*0 .1 > p > 0 .05 (T = .1 98) ; B max =
maximal number of binding sites ;
ICYP = iodine-1 5-iodocyanopindolol ; NS = not significantly different
(T = 1 . 98) when compared with the corresponding values in patients with
mitral regurgitation
. Given are mean values ± SEM ; the number of patients is
in parentheses
.
Left Atrium Left Ventricle
40 .8 ± 7 .7 (8) 0.8 ± 4 .4 (8)
74 .9 ± 16 .9
(3)* 30.3 ± 6 .5 (4)NS
38 .4 ± 6 .1 (10) .3
±
.6 (1 )
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Figure 3 . Correlation between left ventricular beta-adrenoceptor
density (ordinate) and total plasma catecholamine (norepinephrine
plus epinephrine) levels (abscissa) in 10 patients with mitral valve
disease . Abbreviations as in Figure 1 .
valve disease . In these 10 patients, plasma norepinephrine
(4 8.1 ± 31 [range 76 to 600] pg/ml) and plasma epinephrine
( 95.7 ± 9 [range 1 to 718] pg/ml) were significantly
(p < 0.01) higher than in 31 patients with coronary artery
disease without apparent heart failure (norepinephrine
73 .6 ± 1 [range 177 to 4 31 pg/ml, epinephrine 11 ± 14
[range to 3] pg/ml) . In this limited number of pa-
tients, left ventricular beta-adrenoceptor number correlated
neither with plasma norepinephrine nor plasma epinephrine,
but was (weakly) inversely correlated with total plasma
catecholamine (norepinephrine plus epinephrine) levels
(Fig . 3) .
Contractile responses of isolated electrically driven cardiac
preparations from patients with mitral valve disease to beta-
adrenoceptor agonists . We (13) recently showed that in the
isolated electrically driven right atrial strips from patients
with coronary artery disease (functional class I to II),
isoproterenol produced its positive inotropic effect through
stimulation of beta,- and beta,-adrenoceptors, whereas nor-
epinephrine produced its effect solely through beta,-
adrenoceptor stimulation (18) and the selective beta,-
adrenoceptor agonist procaterol produced its effect
predominantly through beta,-adrenoceptor stimulation . In
the patients with mitral valve disease (functional classes III
and III-IV) the concentration-response curves for all three
agonists were shifted to the right to higher concentrations to
about the same degree (Table 3, Fig . 4), which is in good
agreement with the concomitant decrease in right atrial
beta,- and beta,-adrenoceptors (Fig . l) .
In the isolated electrically driven left atrial strips, isopro-
terenol also produced a concentration-dependent increase in
contractile force . (Fig . 5) ; its pD value (6 .18 ± 0 .19, n = 6),
however, was even lower than that in the right atrium . The
highly selective beta,-adrenoceptor antagonist ICI 118,551
(3 x 10 -R mol/liter) (14) and the highly selective beta,-
BRODDE ET AL . 3 7
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Table 3 . pD, Values for the Positive Inotropic Effects of
Isoproterenol, Norepinephrine and Procaterol on Isolated
Electrically Driven Right Atrial Strips From Patients With Mitral
Valve Disease (functional class III and III to IV) in Comparison
With Patients With Coronary Artery Disease Without Apparent
Heart Failure (class I to II)
pD, Values
Coronary Mitral Valve
Artery Disease Disease
*p < 0 .01 : ip < 0 .0 5 : tO.l > p > 0 .05 (T = .0665) versus the corre-
sponding values in patients with coronary artery disease . Given are mean
values ± SEM : number of patients investigated is in parentheses . In the
isoproterenol experiments, two patients were in class III and two patients in
class III to IV . The procaterol and norepinephrine experiments were per-
formed simultaneously in the same three patients ; one patient was in class III
and two were in class III to IV . Data for patients with coronary artery disease
were taken from References 13 and 18 . pD, value = negative logarithm of the
molar concentrations of the beta-adrenoceptor agonists that cause 50% of
maximal response .
adrenoceptor antagonist CGP 071 A (3 x 10-7 mol/liter)
(19)-both used in a concentration that occupies >90% of
beta,- and beta,-adrenoceptors, respectively-shifted the
concentration-response curve for isoproterenol to the right
to about the same degree . The combination of both antago-
nists resulted in a further marked shift to the right demon-
strating, for the first time, that in the human left atrium, both
beta,- and beta,-adrenoceptors can contribute to the positive
inotropic effect of beta-adrenoceptor agonists .
In the left papillary muscles, on the other hand, there was
mainly a rightward shift of ICI 118,551 in the lower part of
the concentration-response curve for isoproterenol (Fig . 6),
whereas CGP 071 A shifted mainly the upper part of the
curve. Thus, antagonism of both selective antagonists re-
sulted in shallow agonist concentration-response curves .
However, combination of both CGP 071 A and ICI 118,551
resulted in a further, now parallel shift of the concentration-
response curve for isoproterenol (Fig . 6) to the right, indi-
cating that in human left papillary muscles both beta,-
adrenoceptors (to a major extent) and beta -adrenoceptors
(to a minor extent) are involved in the positive inotropic
action of isoproterenol . Similar to the beta-adrenoceptor
number in left papillary muscles, however, the pD value for
isoproterenol-induced positive inotropic effect gradually de-
creased when the degree of heart failure increased (Fig . 7) .
Effects of forskolin on contractile responses to beta-
adrenoceptor agonists on isolated electrically driven cardiac
preparations from patients with mitral valve disease . Finally,
we studied whether in the isolated electrically driven left
atrial strips and left papillary muscles direct stimulation of
adenylate cyclase may induce additional positive inotropic
effects. For this purpose we determined the effects of 10-e
Isoproterenol 7 .73 ± 0 .1 (8) 6 .63 ± 0. 6 (4)*
Norepinephrine 6 .80 ± 0 . 1 (3) 5 .91 ± 0 .14 (3)t
Procaterol
8 .03
± 0
.18
(9)
7 .43 ± 0
.14 (3)$
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8
mol/liter forskolin-which directly activates the catalytic
unit of the adenylate cyclase (
0)-on the maximal positive
inotropic effects of isoproterenol and epinephrine (Fig
. 8) .
This concentration of forskolin, added to the organ bath
when saturating concentrations of isoproterenol and epi-
nephrine had induced maximal positive inotropic effects,
produced additional increases in developed tension that
were similar to or even greater than the maximal responses
to the catecholamines .
Discussion
Functional importance of beta,- and beta -adrenoceptors in
the human atrium and left papillary muscle . Considerable
evidence has accumulated in the past few years that in the
human heart both beta,- and beta -adrenoceptors coexist .
Stimulation of both beta-adrenoceptor subtypes contributes
Figure 5. Effects of 3 x 10 -7 mol/liter CGP 071 A and
3 x 10-a
mol/liter ICI 118,551 on the positive inotropic effect ofisoproterenol
on the isolated electrically driven left atrial appendage derived from
patients with mitral valve disease (New York Heart Association
classes III to IV) . Format as in Figure 4 .
100-0-0 Control (6)
_ •- -• CGP 071 A (4)
ICI 118,551(4)
80-
o--o CGP+ICI(5)
N
W ~ ~
60-
w o
W
)%
to the positive inotropic effect of beta-adrenoceptor ago-
nists . Whereas in the isolated electrically driven right atrial
strip, obviously both beta,- and beta -adrenoceptors can
mediate maximal positive inotropic effects (13,18, 1), in
right (11) and left papillary muscles ( 1), the maximal posi-
tive inotropic effect mediated by beta -adrenoceptor stimu-
lation is significantly less than that mediated by beta,-
adrenoceptor stimulation. The present results are in
accordance with these observations. They show that in
isolated electrically driven left papillary muscles of patients
suffering from mitral valve disease (functional class III to IV)
the positive inotropic effect of low concentrations of isopro-
terenol is more potently antagonized by the selective beta -
adrenoceptor antagonist ICI 118,551 than by the selective
beta, -adrenoceptor antagonist CGP 071 A. At higher con-
Figure 6 . Effects
of 3 x 10 -7 mol/liter CGP 071 A and 3 x 10
-8
mol/liter ICI 118,551
on the positive inotropic effect of isoproterenol
on the isolated electrically driven left papillary muscle derived from
patients with mitral valve disease (New York Heart Association
classes III to IV)
. Format as in Figure 4 .
100-
80
M
R 60-
u fO O
C , 40-
o
0 0
0-
Figure 4 . Positive inotropic effects of isoproterenol,
procaterol and norepinephrine (ordinate) on isolated
electrically driven right atrial appendage from patients
with mitral valve disease ([MVD], functional classes
III and III to IV) in comparison with effects in patients
with coronary artery disease (CAD) without apparent
heart failure (functional classes I and II) . Molar con-
centrations of the beta-adrenoceptor agonists are on
the abscissa . The number of experiments is in paren-
theses. Values are mean values ± SEM . Data for
patients with coronary artery disease were taken from
References 13
and
18 .
0-0
Control (15)
--• CGP (171 A(13)
- - • ICI 118,551(7)
o--o CGP+ICI (7)
~~
1
i
.;
I ' , I I ,
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U4
10r3 mol/l
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i
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Figure 7. Beta-adrenoceptor density (A) and contractile response
to isoproterenol (B) of left papillary muscle derived from patients
with mitral valve disease in relation to the degree of heart failure .
Ordinate (upper panel) : Left ventricular beta-adrenoceptor density
in fmol ICYP specifically bound per milligram of protein . Lower
panel : pDz value for the positive inotropic effect of isoproterenol .
ICYP = iodine-1 5-iodocyanopindolol; NYHA = New York Heart
Association Functional class ; pD value = negative logarithm of the
molar concentration of isoproterenol that causes 50% of maximal
response .
centrations of the agonist, ICI 118,551 had less effect,
whereas CGP 071 A markedly shifted the concentration-
response curve of isoproterenol to the right . This result is
consistent with the view that, in human left papillary mus-
cles, beta,-adrenoceptor stimulation evokes only a submax-
imal positive inotropic effect .
On the other hand, in isolated electrically driven left atrial
strips, both ICI 118,551 and CGP 071 A produced a nearly
Figure 8. Effects of 10-' mol/liter forskolin on the maximal positive
inotropic effect (increase in contractile force) evoked by saturating
concentrations of isoproterenol or epinephrine on isolated electri-
cally driven left papillary muscle or left atrial appendage from
patients with mitral valve disease (classes III to IV) .
Agonists alone l
• Agonists subsequently I
10 - 6mo[/L Forskolin
') p< 0.05 vs
. the corresponding control
l
l
Left Atrium
Isoproterenol
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parallel rightward shift of the concentration-response curve
of the positive inotropic effect of isoproterenol . However,
both antagonists produced a rightward shift that was less
than could be predicted assuming that only one beta-
adrenoceptor subtype mediates the positive inotropic action
of isoproterenol. This result suggests that both beta,- and
beta,-adrenoceptors are involved in the positive inotropic
action of isoproterenol in the left atrium to about the same
degree . This assumption is supported by the fact that the
combination of both selective antagonists produced a re-
markable further parallel rightward shift of the concentra-
tion-response curve of isoproterenol . These results, there-
fore, are in favor of the concept, that in the human left
atrium (similar to the right atrium) both beta,- and beta -
adrenoceptors can mediate maximal isotropic effects of
beta-adrenoceptor agonists .
Cardiac beta,- and beta -adrenoceptor changes in patients
with mitral valve disease . Several investigations ( - 5)
have demonstrated that in patients with chronic congestive
cardiomyopathy cardiac beta-adrenoceptor density and
functional responsiveness are decreased ( - 4), and the
magnitude of this reduction seems to be related to the degree
of heart failure ( 5) . The present results confirm and extend
these observations: they clearly show that in patients with
mitral valve disease beta-adrenoceptor density in the right
and left atrial as well as in left ventricular myocardium
gradually decreases, when the degree of heart failure in-
creases from functional class III to IV . It is interesting to
note that changes in beta-adrenoceptor density were only
related to functional class but not to any of the preoperative
hemodynamic variables . This observation is in good agree-
ment with recently published data ( 6- 9) that in patients
undergoing mitral valve replacement the most predictive
independent determinant of postoperative mortality due to
myocardial failure was advanced functional class .
Heart failure in mitral valve disease versus congestive
cardiomyopathy . According to the present data, the de-
crease in atria, and ventricular beta-adrenoceptor density
was due to a concomitant decrease in both beta,- and
beta,-adrenoceptor subtypes . Thus, in all tissues the relative
amount of beta,- and beta -adrenoceptors was relatively
constant irrespective of the degree of heart failure . These
results are in contrast to the recently reported (11,1 )
selective down regulation of beta, -adrenoceptors in patients
suffering from end-stage congestive cardiomyopathy . The
reason for this differential (pathophysiologic) regulation of
human cardiac beta,- and beta,-adrenoceptors in congestive
cardiomyopathy and mitral valve disease is not known at
present. One possible explanation is that the patients with
mitral valve disease, although in functional class III to IV,
had less severe left ventricular dysfunction (ejection fraction
56% to 65%, cardiac index .3 to .5) (Table 1) than had the
patients with end-stage congestive cardiomyopathy (ejection
fraction 13% to 0%, cardiac index 1 .6 to . ) (11,1 ) . Thus,
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it may be that early in heart failure beta,- and beta -
adrenoceptors concomitantly decrease, whereas with more
severe left ventricular dysfunction there is a rather greater
decrease in the number of beta,-adrenoceptors .
Another possible explanation is that catecholamines are
affected differently in the two forms of diseases
. It has
repeatedly been shown (1-6) that in patients with congestive
cardiomyopathy plasma norepinephrine levels are markedly
increased ; in fact, plasma norepinephrine levels have been
suggested to be a predictor of survival rate of patients (6) . In
addition, in a recent study (30), cardiac norepinephrine
spillover to plasma was found to be increased in these
patients . On the other hand, plasma epinephrine levels vary
and are more often normal in patients with congestive
cardiomyopathy (1) . Because norepinephrine is a rather
selective beta ,-adrenoceptor agonist (10), it might be possi-
ble that the elevated norepinephrine levels in patients with
congestive cardiomyopathy selectively down regulate only
beta, -adrenoceptors without affecting beta -adrenoceptors .
Such a selective beta s-adrenoceptor down regulation caused
by norepinephrine has been observed in different experimen-
tal animal models (31-33) ; in rats (31,3 ) implanted with a
norepinephrine-secreting pheochromocytoma in several tis-
sues, only beta, -adrenoceptor density was reduced . Simi-
larly, in rabbits (33) long-term infusion of norepinephrine
resulted in a significant decrease of beta-adrenoceptor den-
sity in tissues possessing predominantly beta, -adrenoceptors
(heart and lung), but not in circulating lymphocytes contain-
ing exclusively beta -adrenoceptors . On the other hand, the
second endogenous catecholamine, epinephrine, is a nonse-
lective beta-adrenoceptor agonist having an equal affinity to
beta,- and beta -adrenoceptors (10); accordingly, it could
lead to a concomitant down regulation of beta,- and beta -
adrenoceptors .
Taking these observations into consideration, it might be
that in patients with mitral valve disease, plasma epineph-
rine, in addition to norepinephrine, is elevated and this may
cause the concomitant decrease in cardiac beta,- and beta -
adrenoceptors . Although we could determine plasma cate-
cholamines in only a limited number of patients, these
preliminary data seem to support this assumption . Left
ventricular beta-adrenoceptor number was (even if weakly)
significantly inversely correlated only with total plasma
catecholamines, but not with norepinephrine or epinephrine
alone (Fig . 3) . Moreover, it was recently reported (34) that,
in patients with mitral valve disease, very mild exercise
produced markedly higher increases in plasma norepineph-
rine and epinephrine levels than those produced in healthy
control subjects, and this increase was more pronounced as
the severity of the disease increased . However, determina-
tion of plasma catecholamines in many more patients is
needed to ascertain whether in fact, both norepinephrine and
epinephrine are elevated in mitral valve disease .
JACC Vol. 14, No
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Clinical implications . In the present study, the decrease
in cardiac beta-adrenoceptor density in patients with mitral
valve disease was accompanied by a similar decrease in
contractile responses to beta-adrenergic stimulation . In
the isolated electrically driven right atrial myocardium,
the pD values for the positive isotropic effects of isopro-
terenol (beta,- and betazmediated), norepinephrine (beta,-
mediated) and procaterol (beta -mediated) were significantly
lower than values obtained in patients undergoing coronary
artery bypass grafting without apparent heart failure (13,18) .
The fact that a similar decrease in pD values was obtained
for all three agonists further supports the view that, in
patients with mitral valve disease, both cardiac beta,- and
beta -adrenoceptors are decreased to about the same extent .
Moreover, in left papillary muscles the pD value for the
isoproterenol-induced positive inotropic effect gradually de-
clined, in a very similar manner as the beta-adrenoceptor
density when the degree of heart failure increased from
functional class III to class IV . These results agree with
those in the recently reported observation ( 5) that the
positive inotropic effect of graded infusion of dobutamine
was significantly less in patients with severe heart failure
than in patients with mild to moderate heart failure . Taking
these and the present results into consideration, it can be
concluded that patients with mitral valve disease have de-
creased cardiac beta,- and beta -adrenoceptor function, and
that this decrease is related to the degree of heart failure .
In the present study forskolin-which directly activates
the catalytic unit of the adenylate cyclase ( 0) -adding to the
positive inotropic effects of saturating concentrations of
isoproterenol or epinephrine, produced an additional in-
crease in contractile force in left atrial and left papillary
muscles . The mechanism underlying these additional posi-
tive inotropic effects, which have been observed also in
patients suffering from end-stage congestive cardiomyopa-
thy (35), is not completely understood . It might be that
forskolin stimulates the adenylate cyclase distal from the
beta-adrenoceptor (35) ; another possibility is that forskolin
enhances coupling of the beta-adrenoceptor to the catalytic
unit of the adenylate cyclase as has been shown in an intact
cell system, the S-49 lymphoma cells (36) .
Conclusions . Our data are consistent with the view that a
decrease in cardiac beta-adrenoceptor function is a general
phenomenon in heart failure, and this decrease is related to
the degree of heart failure (as evaluated by clinical functional
class). However, in contrast to the selective loss of beta,-
adrenoceptors in congestive cardiomyopathy, in mitral valve
disease the reduction in beta-adrenoceptor function is due
to a concomitant decrease in cardiac beta,- and beta -
adrenoceptors . The mechanism underlying this differential
regulation of cardiac beta,- and beta -adrenoceptors in dif-
ferent forms of heart failure remains to be elucidated .
JACC Vol . 14, No .
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